Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer’s disease
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1758-9193
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer’s disease ; volume:12 ; number:1 ; day:22 ; month:1 ; year:2020 ; pages:1-12 ; date:12.2020
Alzheimer's research & therapy ; 12, Heft 1 (22.1.2020), 1-12, 12.2020
- Urheber
-
Yoshida, Kenta
Moein, Anita
Bittner, Tobias
Ostrowitzki, Susanne
Lin, Helen
Honigberg, Lee
Jin, Jin Y.
Quartino, Angelica
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13195-020-0580-2
- URN
-
urn:nbn:de:101:1-2020042501223659929196
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:51 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Yoshida, Kenta
- Moein, Anita
- Bittner, Tobias
- Ostrowitzki, Susanne
- Lin, Helen
- Honigberg, Lee
- Jin, Jin Y.
- Quartino, Angelica
- SpringerLink (Online service)
Ähnliche Objekte (12)
Dysphagia is closely related to frailty in mild-to-moderate Alzheimer’s disease
Increased Levels of Antigen-Bound beta-Amyloid Autoantibodies in Serum and Cerebrospinal Fluid of Alzheimer's Disease Patients
Cerebrospinal fluid soluble TREM2 in aging and Alzheimer’s disease
Cerebrospinal Fluid Profile of Lipid Mediators in Alzheimer’s Disease
Transgenic tomatoes expressing human beta-amyloid for use as a vaccine against Alzheimer’s disease
Estimating attrition in mild-to-moderate Alzheimer’s disease and mild cognitive impairment clinical trials
Aquaporin-4 as a cerebrospinal fluid biomarker of Alzheimer’s disease
Genome-wide meta-analysis for Alzheimer’s disease cerebrospinal fluid biomarkers
Spatial pattern of beta-amyloid accumulation in Alzheimer’s disease as measured with positron emission tomography
![Selektion hochaffiner RNA-Moleküle gegen das Alzheimer β-Amyloid [Beta-Amyloid]](/assets/placeholder/searchResultMediaNoDigitisedMedia.png)
Selektion hochaffiner RNA-Moleküle gegen das Alzheimer β-Amyloid [Beta-Amyloid]
Selektion hochaffiner RNA-Moleküle gegen das Alzheimer β-Amyloid [Beta-Amyloid]
Metabolite profiling of Alzheimer's disease cerebrospinal fluid
Dysphagia is closely related to frailty in mild-to-moderate Alzheimer’s disease
Increased Levels of Antigen-Bound beta-Amyloid Autoantibodies in Serum and Cerebrospinal Fluid of Alzheimer's Disease Patients
Cerebrospinal fluid soluble TREM2 in aging and Alzheimer’s disease
Cerebrospinal Fluid Profile of Lipid Mediators in Alzheimer’s Disease
Transgenic tomatoes expressing human beta-amyloid for use as a vaccine against Alzheimer’s disease
Estimating attrition in mild-to-moderate Alzheimer’s disease and mild cognitive impairment clinical trials
Aquaporin-4 as a cerebrospinal fluid biomarker of Alzheimer’s disease
Genome-wide meta-analysis for Alzheimer’s disease cerebrospinal fluid biomarkers
Spatial pattern of beta-amyloid accumulation in Alzheimer’s disease as measured with positron emission tomography
Selektion hochaffiner RNA-Moleküle gegen das Alzheimer β-Amyloid [Beta-Amyloid]
Selektion hochaffiner RNA-Moleküle gegen das Alzheimer β-Amyloid [Beta-Amyloid]
Metabolite profiling of Alzheimer's disease cerebrospinal fluid
Dysphagia is closely related to frailty in mild-to-moderate Alzheimer’s disease
Increased Levels of Antigen-Bound beta-Amyloid Autoantibodies in Serum and Cerebrospinal Fluid of Alzheimer's Disease Patients
Cerebrospinal fluid soluble TREM2 in aging and Alzheimer’s disease
Cerebrospinal Fluid Profile of Lipid Mediators in Alzheimer’s Disease
Transgenic tomatoes expressing human beta-amyloid for use as a vaccine against Alzheimer’s disease
Estimating attrition in mild-to-moderate Alzheimer’s disease and mild cognitive impairment clinical trials
Aquaporin-4 as a cerebrospinal fluid biomarker of Alzheimer’s disease
Genome-wide meta-analysis for Alzheimer’s disease cerebrospinal fluid biomarkers
Spatial pattern of beta-amyloid accumulation in Alzheimer’s disease as measured with positron emission tomography
Selektion hochaffiner RNA-Moleküle gegen das Alzheimer β-Amyloid [Beta-Amyloid]
Selektion hochaffiner RNA-Moleküle gegen das Alzheimer β-Amyloid [Beta-Amyloid]